Medicare Enrolled
Dr. Muffaddal Morkas, MD
Optician · Houston, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Morkas from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Morkas?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Morkas
Dr. Muffaddal Morkas is an optician specialist in Houston, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Morkas performed 28,353 Medicare services across 1,433 unique beneficiaries.
Between the years covered by Open Payments, Dr. Morkas received a total of $5,886 from 34 pharmaceutical and/or device companies across 91 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Morkas is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in TX
$5,886 industry payments
Medicare Practice Summary
Medicare Utilization ↗28,353
Medicare services
Top 2% in TX for optician
1,433
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,492 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
8,630 | $2 | $20 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
8,100 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,050 | $0 | $5 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
820 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
722 | $8 | $36 |
| Anti-nausea injection (Aloxi/palonosetron) | 620 | $1 | $114 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
493 | $8 | $20 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
355 | $63 | $250 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
264 | $96 | $368 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
173 | $23 | $157 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
113 | $11 | $96 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
113 | $103 | $707 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
88 | $50 | $313 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
76 | $35 | $143 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
74 | $27 | $145 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
68 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
68 | $6 | $34 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 66 | $139 | $3,675 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
57 | $12 | $108 |
| Erythrocyte sedimentation rate (ESR) test A blood test that measures how quickly red blood cells settle in a test tube to detect inflammation in the body. This specific method is performed manually rather than using an automated machine. |
56 | $4 | $33 |
| New patient office visit, complex (60-74 min) | 56 | $171 | $709 |
| Automated red blood cell count with calculations A blood test that automatically counts red blood cells and performs additional calculations to assess blood health. |
44 | $5 | $26 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
43 | $23 | $161 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
36 | $17 | $100 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
35 | $52 | $344 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
35 | $1 | $7 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
33 | $136 | $496 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
29 | $117 | $565 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
23 | $4 | $30 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 13 | $13 | $36 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.6% high complexity
90.1% medium
8.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,886
Total received (2018-2024)
Avg $981/year across 6 years
Top 24% in TX for optician
34
Companies
91
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,726 (63.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,745 (29.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$416 (7.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$947
2023
$753
2022
$225
2021
$26
2019
$28
2018
$3,908
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$3,969
Janssen Biotech, Inc.
$369
GENZYME CORPORATION
$130
Novartis Pharmaceuticals Corporation
$126
Regeneron Healthcare Solutions, Inc.
$122
Medtronic, Inc.
$108
Astellas Pharma US Inc
$91
Merck Sharp & Dohme LLC
$79
Celgene Corporation
$72
Gilead Sciences, Inc.
$70
Karyopharm Therapeutics Inc.
$66
E.R. Squibb & Sons, L.L.C.
$58
BeiGene USA, Inc.
$55
Boston Scientific Corporation
$54
Incyte Corporation
$48
ABBVIE INC.
$48
Immunocore Limited
$33
Stemline Therapeutics Inc.
$31
Amgen Inc.
$30
Rigel Pharmaceuticals, Inc.
$28
Daiichi Sankyo Inc.
$27
EMD Serono, Inc.
$26
Boehringer Ingelheim Pharmaceuticals, Inc.
$26
ADC Therapeutics America, Inc.
$26
Bayer Healthcare Pharmaceuticals Inc.
$24
CTI BioPharma Corp.
$24
GlaxoSmithKline, LLC.
$23
TAIHO ONCOLOGY, INC.
$21
Sirtex Medical Inc
$21
AstraZeneca Pharmaceuticals LP
$19
Genentech USA, Inc.
$19
ARRAY BIOPHARMA INC
$17
Puma Biotechnology, Inc.
$13
Seattle Genetics, Inc.
$12
Top 3 companies account for 75.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · Alecensa · BAVENCIO · BOSULIF · BRUKINSA · CARVYKTI · DARZALEX · ENHERTU · ENJAYMO · EPKINLY · Enhertu · Fabhalta · GILOTRIF · IBRANCE · IMBRUVICA · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KIMMTRAK · LONSURF · LUMAKRAS · LUPRON DEPOT · Neulasta · Nubeqa · OJJAARA · OPDIVO · OSTEOCOOL RF ABLATION SYSTEM · Orserdu · PADCEV · PRALUENT ALIROCUMAB INJECTION · PROMACTA · Padcev · REBLOZYL · RYBREVANT · Rezlidhia · SCEMBLIX · SIR-Spheres Microspheres · TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) · Trodelvy · Vonjo · XALKORI · XPOVIO · XTANDI · Xospata
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (63%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $21 per 100 Medicare services performed
Geographic Context
Opticians within 10 mi
523
Per 100K population
11.0
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN MEMORIAL CITY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Morkas is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), with consulting-driven industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Morkas experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Morkas performed 8,630 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Morkas receive payments from pharmaceutical companies?
Yes. Dr. Morkas received a total of $5,886 from 34 companies across 91 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Morkas's costs compare to other opticians in Houston?
Dr. Morkas's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Morkas) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Houston
Browse opticians in Houston ranked by procedure volume and transparency data.
Highest volume
Top Opticians in TX
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in TX
Which TX opticians receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology